Introduction
Abdominal aortic aneurysm (AAA) is a common vascular disease of the aorta, characterized by medial degeneration and chronic aortic wall inflammation. Ruptured AAA is one of the leading causes of death particularly in men and women aged over 60 years. 1 Despite recent advances in the understanding of its pathophysiological mechanisms, medical therapeutic options limiting aneurysm growth and/or rupture are still limited. 2 The physiopathology of non-syndromic AAA is complex, including elastin degradation, collagen remodelling, smooth muscle cell apoptosis, and accumulation of inflammatory cells. 3, 4 Several experimental studies have documented the importance of the imbalance between metalloproteinases and metalloproteinase inhibitors in the progression of the disease. Matrix metalloproteinase (MMP)-2 and MMP-9 are abundantly expressed in the aneurysmal wall whereas expression levels of Tissue Inhibitor of MetalloProteinases (TIMPs) are decreased. 5 In several mouse models of AAA, genetic knockout of Mmp-2 or Mmp-9 prevented the development of aortic aneurysmal lesions. 6, 7 In addition, in apoE À/À mice, Mmp-9 genetic deletion protected against atherosclerotic media destruction and ectasia. 8 Similarly, overexpression of Mmp-9 inhibitors such as plasminogen activator inhibitor 1 and Timp-1 induced arterial aneurysm stabilization in rats. 9, 10 Despite encouraging beneficial results, these gene transfer strategies are not easy to develop in humans. Our group and others proposed original approaches based on local cell therapy. Allaire et al. reported that endovascular transplantation of vascular smooth muscle cells (VSMCs) prevented AAA progression in a rodent model. Later, the same group showed that endovascular seeding of bone marrow (BM) mesenchymal stem cells decreased the expansion of AAA diameter more efficiently than VSMCs. 11 However, the isolation of BM cell remains an outsized procedure requiring local and/or general anaesthesia, needle insertion in the bone and BM aspiration. Use of fibroblasts from oral mucosal gingiva represents a promising alternative for cell therapy because of the high regeneration potential, foetal-like phenotype and anti-inflammatory properties of gingival fibroblasts (GFs). 12 GFs have been used successfully to repair vocal fold scarring, 13 tracheal injury 14 and to correct urethral strictures. 15 Recently, we developed a cell-based treatment using GFs. In vitro, GFs produced TIMP-1 16 and anti-inflammatory cytokines such as interleukin-10 (IL-10) and TGF-b. 17 In vivo, human GF endovascular engraftment in rabbit carotid artery, after elastase infusion, resulted in a significant reduction of local dilation. Local GF deposition was associated with a decrease of the Mmp-9/Timp-1 ratio. 17 Despite encouraging conclusions, the relevance of these findings remains questionable for several reasons. First, the experimental protocol included a xenograft of human GFs in rabbit vascular tissue. Second, observations were done in a model of carotid dilation that is far from aortic aneurysm pathophysiology. Finally, the mechanisms of arterial protection induced by GF cell-based treatment have not been directly addressed.
In this study, we developed a cell therapy approach using graft of GFs in two different mouse models of AAA. We showed that mouse GFs when deposited on the adventitia around the abdominal aorta were able to survive and proliferate, and organize in an adventitial layer structure. GFs limited vascular wall degradation, innate, and adaptive immune cell accumulation and prevented aneurysm progression and rupture. Genetic knockout of Timp-1 in GFs abolished their vascular protective functions. Sigma-Aldrich (St. Louis, MO, USA), and ALZET osmotic pumps were from Charles River Laboratories.
Methods

Animals
Characterization of aneurysmal lesions
Both cryostat and paraffin-embedded aortic sections were used. GF proliferation was defined as the per cent of Ki67þ cells among TomatoFluorescent Proteinþ cells. Elastin staining was visualized using Orcein, the number of elastin layers was quantified by a researcher blinded to the experimental protocol (four measurements/section). Sections were stained for collagen using Sirius Red, T lymphocytes using anti-CD3 antibody (Dako), and macrophages using anti-mouse CD68 antibody (Serotec). Terminal dUTP nick end-labelling (TUNEL) staining was performed using In Situ Cell Death Detection Kit (histochemistry staining). The suprarenal region of the abdominal aorta containing AAAs was serially cross-sectioned (8 lm sections). The per cent of cellular area with positive staining (macrophages or T cells) was quantified using Histolab software (Microvision) and defined as the ratio stained area/aortic wall area (media þ adventitia). The quantification was done on eight serial aortic sections and the mean was recorded for each mouse.
Chitosan hydrogel
Chitosan hydrogel was prepared as described by Fatimi et al. 20 Briefly, chitosan solution was made by dissolving 2 g of chitosan powder (SigmaAldrich) in aqueous hydrochloride solution and deionized water at room temperature under constant magnetic stirring for 24 h. Chitosan solution was sterilized by autoclaving at 121 C for 20 min and kept at 4 C. b-Glycerophosphate (b-GP) 12% solution was prepared by dissolving b-GP powder in Opti-MEM medium and sterilized using a 0.22 mm filter. b-GP solution was mixed with chitosan solution at ratio 1:2, respectively, before immediate use. Chitosan hydrogel was used as a biodegradable inert glue that maintains cells in the peri-aortic area following engraftment.
Culture of mouse GFs
Mouse GFs were isolated from gingiva of C57BL/6J male mice (6-weekold) and cultured in 75 cm 2 culture flasks in DMEM/F12 medium with 20% fetal calf serum (FCS), 4 ng/mL of Fibroblast growth factor-2 (FGF-2), 200 UI/mL penicillin, 200 mg/mL streptomycin, 2.5 mg/mL amphotericin B. Mice were anaesthetized with 2% isoflurane in oxygen and then were euthanized before gingiva was dissected. Medium culture was changed every 2 days ( Figure 1A) . 
Ang II/anti-TGF-b AAA model
AAAs were induced in normocholesterolemic C57BL/6J mice by subcutaneous infusion of Ang II (Sigma-Aldrich) at 1000 ng/kg/min for 28 days (mini-pumps Alzet, Charles River), along with systemic neutralization of TGF-b (ip injection of 500 lg, 3 times per week; Biotem), as previously described. 18 For pump implantation, animals were anesthetized with 2% Isoflurane and received 0.05 mg/kg s.c. buprenorphine. A fivepoint grading system was used to classify aneurysms adapted from Daugherty's definition 22 : Type 0: Normal aorta. Type I, dilated lumen in the supra-renal region of the aorta with no thrombus. Type II, remodelled tissue in the supra-renal region that frequently contains thrombus. Type III, a pronounced bulbous form of Type II that contains thrombus. Type IV, a form in which there are multiple aneurysms containing thrombus, some overlapping, in the suprarenal area of the aorta or rupture. At Day 7 of Ang II infusion, mice were anaesthetized with 2% Isoflurane and received 0.05 mg/kg buprenorphine in 1 mL s.c. 0.9% NaCl administration. A laparotomy was performed, AAA stage was recorded and chitosan hydrogel (with or without 2.5 Â 10 6 GF) was engrafted around abdominal aorta, upper celiac trunk (Day 0 of GF cell therapy). Next, the abdominal content was replaced and the ip cavity was closed with 7-0 
Ex vivo reflectance epifluorescence imaging
Mice were anaesthetized with isoflurane and received intravenously 150 mL of a fluorescent imaging probe MMPsense 680 (NEV 10126, PerkinElmer) 24 h before sacrifice. This agent is optically silent in its unactivated state and becomes highly fluorescent following activation by MMPs including MMP-2, -3, -9, and -13. Images were acquired using a fluorescence molecular imaging system (FMT 2500TM, VisEn Medical). 
ELISA
For cytokines and proteins measurements, GF were cultured in flask until 90% confluence, medium was replaced by OptiMEM 0% FCS during 24 h and supernatant was harvested. Il-4, Il-10, Tgf-b, Timp-1 production in the supernatant was measured using specific ELISAs (BD Biosciences and R&D Systems). 
Quantitative real-time PCR
Results
In vitro characterization of mouse GFs
We first developed a protocol to isolate and culture mouse GFs ( Figure 1A) . In vitro, GFs proliferated but were spherical and exhibited no, or very few, pseudopodia extension. However, in a fibroblast growth factor-2-rich medium, GFs showed extended pseudopodia and exhibited elongation, and cell survival was improved (see Supplementary material online, Figure S1 ). Interestingly, mouse GFs exhibited characteristics of mesenchymal stem cells. They showed plastic adherent properties, expressed CD90 (Thy-1) and CD105 (Endoglin) but lacked CD45 expression (see Supplementary material online, Figure S2 ). In addition, GFs expressed receptors involved in cell-cell adhesion, matrix adhesion (CD138) and migration, including CD44 and CD29 (see Supplementary material online, Figure S2 ). GFs were cultured in vitro until Passage 3 to obtain enough cells for in vivo engraftment. As depicted in Figure 1B and C, GFs functions were not impaired at Passage 3 in terms of cytokines (TGF-b, Il-10, and Il-4) and Timp-1 production.
Peri-adventitial GF engraftment
We aimed to develop a local cell therapy based on peri-adventitial engraftment of GFs in an elastase-induced AAA model. After median laparotomy, peri-aortic wall injury was induced by external application of elastase during 5 min. After flushing twice, 2.5Â10 6 GFs, isolated from Rosa mT/mG mouse, enfolded in a chitosan gel, were deposited on the adventitia around the abdominal aorta ( Figure 2A ). Animals were sacrified at Days 3, 7, and 14 after surgery and TomatoFluorescent Proteinþ GFs were analysed by fluorescent microscopy. We confirmed that GFs survived in vivo ( Figure 2B ), proliferated ( Figure 2C) , and organized as in a thick peri-adventitial layer structure.
GFs limited inflammatory cell accumulation
Innate 4,23 and adaptive 18, 25, 26 immunity plays a pathogenic role in the physiopathology of AAA. Immune cells were quantified at Days 7 and 14 following elastase challenge using immunohistochemistry. In the control group, massive macrophage accumulation was observed in the adventitia and the media at Day 7 and to a lower extent at Day 14. T cell accumulation was important both at Days 7 and 14 ( Figure 3) . GF therapy significantly limited CD68þ macrophage accumulation at Day 7 (-55%, P < 0.05) ( Figure 3A) , and CD3 þ T cell accumulation at Day 7
(-39%, P < 0.05) and Day 14 (-48%, P < 0.01) ( Figure 3B) . Finally, we found that GF cell therapy significantly reduced apoptosis within the abdominal aortic media (-55%, P < 0.05) (see Supplementary material online, Figure S3 
GFs prevent aortic wall degradation and AAA formation
Extracellular matrix degradation is a key mechanism in AAA formation, and promotes vascular dilation and progression towards rupture. In the elastase model, elastin degradation is initiated by the application of exogenous elastase. Subsequently, local activation of MMPs with elastinolytic activity (e.g. MMP-9) further contributes to elastin degradation and matrix remodelling. 7, 27 GF deposition limited elastin degradation, as assessed by the significantly higher number of elastin layers in the GF-treated group at Days 7 and 14, compared with the control group: 2.6 ± 0.3 vs 2.0 ± 0.2 (P < 0.05), and 2.2 ± 0.5 vs. 1.5±0.3 (P < 0.05), respectively ( Figure 4A) . GFs also induced an increase in collagen accumulation in the peri-adventitial area ( Figure 4B) . At Day 7, we found a significant reduction of Mmp-9, Mmp-12 mRNA expression and a significant increase of Timp-1 and Col3a1 mRNA expression in the abdominal aortic wall of the GF-treated group ( Figure 4C) . GF cell therapy regulated local inflammatory responses with significantly increased Tgf-b and Il-10 mRNA expression (P < 0.01) and a trend towards reduction in Tnf-a mRNA expression (P = 0.07), in the abdominal aortic wall of the GF-treated group ( Figure 4C) . MMP protease activity in the aortic wall, quantified using ex vivo reflectance epifluorescence imaging, was significantly reduced in the aorta of GF-treated animals compared with controls ( Figure 4D ). 
Genetic deletion of timp-1 in GF abolished the vascular protection
To investigate the causal role of TIMP-1 in the vascular protection induced by GFs, we performed cell therapy experiments using GFs obtained from Timp-1 À/À mice. First, we confirmed that GFs from Timp-1 À/À mice were unable to produce Timp-1 in vitro (see Supplementary material online, Figure S4 ). Then, we locally engrafted wild-type or Timp-1 À/À GF after local administration of elastase. At Day 7, macrophage and CD3 þ T cell accumulation in the adventitia were not significantly different between WT GF-and Timp-1 À/À GF-treated mice (see Supplementary material online, Figure S5 ). In addition, TUNELþ surface area within the media was not different between groups (see Supplementary material online, Figure S6 ). Using qPCR, we found a significant reduction of Timp-1 mRNA expression in the abdominal aorta of Timp-1 À/À GF-treated group ( Figure 5A) . The residual expression of Timp-1 mRNA in the aortic wall of Timp-1 À/À GF-treated mice probably comes from endogenous Timp-1 sources. We also found that reduction of Timp-1 was associated with a marked increase of Mmp-9 expression ( Figure 5A ) and a substantially higher metalloproteinase activity ( Figure  5B ) in the aorta of mice treated with Timp-1 À/À GFs. Timp-1 deficiency in GF cells had no impact on inflammatory cytokine mRNA expression in the abdominal aorta. Next, we addressed the effects of cell therapy on matrix degradation. At Day 7, we found that elastin layer degradation was more pronounced in the group treated with Timp-1 À/À GFs in comparison to the group treated with wild-type GFs ( Figure 5C ) with no difference in collagen content ( Figure 5D ). Finally, we assessed the longterm effect of GF (wild-type or Timp-1 À/À ) engraftment on aneurysm formation. As shown in Figure 6 , wild-type GFs significantly prevented aorta dilatation and AAA formation at Day 28, and the protection was abolished when using Timp-1 À/À GFs. These findings provided strong evidence that GFs protected against aortic wall destruction through Timp-1 production.
GFs prevent AAA rupture
The most deleterious complication of AAA is aneurysm rupture, which is responsible for high mortality and morbidity. 28 Hitherto, no pharmacological treatment is available to prevent aortic rupture. We investigated whether peri-adventitial engraftment of GFs could protect against rupture in a mouse model characterized by frequent AAA-related rupture and sudden death. 18 Seven days before GF cell therapy (Day -7), Figure 7D ) and finally reduced death related to AAA rupture ( Figure 7E) . In contrast, GF cell therapy did not prevent aneurysm formation ( Figure 7C ) and rupture in the thoracic aorta ( Figure 7F) , confirming a local effect on AAA. Finally, the specific gene deletion of Timp-1 in GFs in this second AAA mouse model abolished the beneficial effect of 
GF Control
Discussion
In this study, we showed that GF cell therapy protected against AAA formation and rupture in two different mouse models of aneurysm formation and rupture. GF prevented vascular wall degradation and limited inflammatory cell accumulation within the abdominal aortic wall. Using gene deletion of Timp-1 in GFs, we provided evidence that paracrine Timp-1 production by GFs is a protective mechanism of this therapeutic approach.
It has been previously shown that human GFs exert protective effects in vitro when co-cultured with aortic rings or engrafted in vivo around injured rabbit carotid artery. 17 In the present study, we used two complementary models of aortic aneurysm. Elastase-induced AAA was helpful to analyse in depth the local effects of GF cell therapy on deleterious remodelling of the aortic wall, whereas the AngII/anti-TGFb model helped us to evaluate the effect of GF therapy on aneurysm rupture and death. In elastase AAA model, GF cell therapy was performed at the same time as elastase administration, a situation that is not fully relevant to the clinical setting of aneurysmal disease, which casts doubt on the clinical application of such a therapeutic strategy. Interestingly, in the AngII/anti-TGFb model, GF cells were still protective when engrafted one week after AAA induction, suggesting that GF cell therapy could be beneficial even in patients with established AAA. In this model, we found that GF cell therapy strongly blocked aortic wall destruction and aneurysm progression, but was less efficient at preventing lethal rupture. We focused on MMPs/TIMPs that have been clearly identified as major contributors to the pathophysiology of AAA. Levels of active MMP-2 and MMP-9 are significantly increased in human AAA tissue 29 . In mouse models of AAA, Mmp-2, and Mmp-9 activities in the aortic wall increase over time. 30 Pyo et al. found that the absence of Mmp-9 protected mice from aortic elastase-induced AAA formation. 7 In the periaortic CaCl2 injury model of AAA, lesion formation was fully blocked in both Mmp-9 and Mmp-2 deficient mice. 31 MMP-12 is also expressed in mouse 18 and human 32 aortic aneurysmal tissues, mainly by aortic macrophages. While Mmp-9 is induced after cell activation, Mmp-12 is constitutively expressed by macrophages, and its expression may further be modulated by several stimuli. 33, 34 Our group has previously reported that gene deletion of Mmp-12 reduced AAA severity in the AngII/antiTGFb mouse model. 18 Targeting MMPs is an interesting therapeutic approach for the treatment of aneurysmal disease. Doxycycline, a tetracycline antibiotic, has been shown to non-specifically inhibit MMPs and to limit their gene expression. 35 Several animal studies have demonstrated beneficial effects of doxycycline in preventing AAA. 36 However, clinical trials reported conflicting results. 37 Another approach was based on the modulation of TIMPs, the natural inhibitors of MMPs. An imbalance in MMP:TIMP activity ratio may underlie the pathogenesis of AAA. Genetic knockout of Timp-1 led to increased MMP-2 and MMP-9 activities and worsened aortic aneurysm in both hypercholesterolaemic apoE À/À and non-hypercholesterolaemic C57/Bl6 mouse models. 38, 39 In our study, we used a cell-based treatment with peri-aortic delivery of Timp-1. We found an increase in Timp-1 gene expression in the aorta of GF-treated animals and an important reduction of global metalloproteinase activity, as assessed by reflectance epifluorescence imaging showing pooled proteolytic activity of Mmp-2, Mmp-3, Mmp-9, and Mmp-13. GF cell therapy reduced both Mmp-9 and Mmp-12 mRNA expression, suggesting that Mmp-12 elastase activity was reduced in the vascular tissue. Loss of vascular protection in animals treated with Timp-1 À/À GF clearly indicated the beneficial role of Timp-1 production in this GF cell therapy strategy.
In the AngioII/anti-TGF-b model, GF limited dilatation and rupture specifically in the abdominal aorta, where cells were engrafted, but had no effect on the remote thoracic aorta, suggesting a local paracrine protection. This locally restricted action is of great interest, because MMPs are also involved in several physiological activities, including survival, host defence, tissue repair, or angiogenesis and their systemic inhibition could have harmful side effects. 40 In the elastase AAA model, the vascular protection provided by GF engraftment was totally abolished when we (C) Quantification of aortic diameter in surviving mice at Day 21 after GF cell therapy, n = 7-8 mice/group (two pooled experiments), *P = 0.05 using Kruskal-Wallis test and post hoc analysis (Dunn). Scale bar 1 mm. (D) Quantification of AAA severity within 21 days after GF cell therapy (per cent and absolute number), n = 37 mice in control group, n = 42 mice in WT GF group, n = 23 mice in Timp-1 À/À GF group (four pooled experiments for control and WT GF groups and two pooled experiments for Timp-1 À/À group), using v 2 test for a trend. Survival curves showing mortality related abdominal (E) or thoracic (F) and aneurysm rupture, n = 37 mice in control group, n = 42 mice in WT GF group, n = 23 mice in Timp-1 À/À GF group (four pooled experiments for control and WT GF groups and two pooled experiments for Timp-1 À/À group), NS for non-significant and P < 0.05 using log-rank (Mantel-Cox) test.
Gingival fibroblasts protect against AAA pharmacological alternative for AAA prevention. However, a main issue regarding recombinant protein-based therapy is reduced long-term in vivo protein stability. In the more clinically relevant AngII/anti-TGFb model, AAA rupture was slightly reduced in the Timp-1 À/À GF group even though not reaching statistical significance compared with either the control or the GF-treated group, suggesting that factors other than TIMP-1 might be involved in GF cell-mediated protection. In our study, transferred GF cells organized as a thick layer around the abdominal aorta and survived in vivo until Day 14. GF cells were used at early passage (P3) after in vitro cell culture. We did not find any evidence of cell immortalization. In particular, we never detected tumour in the abdominal peri-aortic cavity at sacrifice. Moreover, in vivo GF cell proliferation decreased after Day 7.
In GF-treated animals, we observed an increase in collagen content that resulted either from a reduction of matrix degradation by Timp-1 and/or increased collagen expression since Col3a1 mRNA expression was also increased in the aorta from mice treated with GFs. However, it is unlikely that GF cell therapy protection was mediated by collagen production because collagen content was similar in protected mice treated with WT GFs compared with unprotected mice engrafted with Timp-1 À/À GF cells. It is more likely that the vascular protection provided by GF cell therapy was mediated at least in part by reduced proteolytic activity of Mmp-9 due to GF-derived Timp-1. The reduction of metalloproteinase activity could also be partially explained by a reduction of Mmp-9 gene expression related to decreased macrophage accumulation. Longo et al. showed that the transfer of Mmp-9 þ/þ BM cells into Mmp-9
À/À mice restored AAA formation, indicating that BM-derived leucocytes are a major source of Mmp-9. 31 However, it is likely that additional factors account for decreased Mmp-9 expression, since Mmp-9 mRNA levels were lower in WT GF group than in Timp-1 À/À GF group, despite no difference of aortic macrophage accumulation between the two groups. The reduction in Mmp-9 gene expression by GF cell therapy may also be due to a modulation of the local immune response associated with reduced Tnf-a and increased Tgf-b and Il-10 expression. Tnf-a 41 and other pro-inflammatory cytokines, including Il-1b 42 have been shown to inhibit smooth muscle cell contractile phenotype and to promote the expression of genes involved in inflammatory/matrix remodelling. In addition, IL-10 per se could promote M2 macrophage 43 and Tr-1 regulatory T cell polarization. 25 Local production of TGF-b by GFs might be responsible for the reduction of both macrophage and T lymphocyte accumulation. However, we believe that production of TGF-b by GFs was unlikely to be a major mechanism of vascular protection because GFs still exerted protection despite neutralization of systemic TGF-b activity in the AngioII/anti-TGF-b model. Despite no direct evidence, our immunohistochemistry and qPCR results suggested that cytokines were locally produced in the abdominal aorta by recruited inflammatory cells. Another potential target that might account for the beneficial effects of GF cell therapy is MMP-13, 34 a powerful collagenase in mice. 44 We found that Mmp-13 mRNA was expressed locally in both models of AAA. Even though no difference in its expression was observed between groups, it is likely that Mmp-13 activity was reduced by Timp-1. In elastase-induced AAA model, wild-type GF cell therapy reduced vascular cell apoptosis. This protective effect might be due to increased production of survival promoting factors, including TGF-b, 45 or reduced local release of cytotoxic molecules due to reduced accumulation of inflammatory cells. Dermal fibroblasts (DFs) could be a potential candidate for cell therapy. However, previous studies reported disappointing outcome in vascular repair with DF as compared with GF cells. In vitro, GF cell therapy prevented aortic ring degradation through MMP-9 inhibition whereas DF had no effect. 16 In a rabbit model of carotid artery aneurysm, endoluminally infused GF cells restored the elastin network and limited artery dilation whereas DF did not. 17 The optimal route for GF cell therapy delivery remains an issue. In our study, GF cell engraftment was performed after abdominal laparotomy, a complex invasive procedure. Other cell delivery routes could be explored such as laparoscopy, a minimally invasive method allowing targeted GF engraftment around the abdominal aorta. Another option is the endovascular route. In the context of atherosclerosis, stem cellcoated stents have been tested in coronary arteries to promote re-endothelialization. 46 In the context of AAA, Riera del moral et al. recently proposed an endovascular strategy for cell engraftment. 47 A coated stent was first inserted to isolate the aneurysm sac from the aortic lumen and then allogeneic stem cells were injected into the sac. This less invasive strategy is promising and deserves to be tested in the future to locally engraft GFs.
Conclusion
Using two complementary mouse models, we provide evidence that peri-adventitial GF engraftment represents a promising approach to inhibit aneurysm progression and rupture through local production of Timp-1.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
Conflict of interest:
Antoine Lafont is co-founder of Scarcell therapeutics, a company developing GFs cell therapy. There is no conflict of interest for all the other authors.
